(±)-HIP-ACAS# 227619-64-9 |
- Alvespimycin
Catalog No.:BCC1346
CAS No.:467214-20-6
- 17-AAG (KOS953)
Catalog No.:BCC2121
CAS No.:75747-14-7
- Retaspimycin
Catalog No.:BCC1889
CAS No.:857402-23-4
- PU-H71
Catalog No.:BCC1872
CAS No.:873436-91-0
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 227619-64-9 | SDF | Download SDF |
| PubChem ID | 55254720 | Appearance | Powder |
| Formula | C6H8N2O4 | M.Wt | 172.14 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 10 mM in sterile water | ||
| Chemical Name | 3-oxo-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d][1,2]oxazole-4-carboxylic acid | ||
| SMILES | C1C2C(C(N1)C(=O)O)C(=O)NO2 | ||
| Standard InChIKey | XJSXFNHFIBCTDU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C6H8N2O4/c9-5-3-2(12-8-5)1-7-4(3)6(10)11/h2-4,7H,1H2,(H,8,9)(H,10,11) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent, non-competitive excitatory amino acid transporter (EAAT) blocker. Preferentially inhibits glutamate-induced [3H]D-aspartate release (IC50 = 1.6 μM) rather than [3H]L-glutamate uptake (IC50 = 18 μM). Moderately selective; displays no affinity for NMDA and metabotropic glutamate receptors, and low affinity for AMPA and kainate receptors (IC50 values are 43 and 8 μM respectively). . |
(±)-HIP-A Dilution Calculator
(±)-HIP-A Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.8092 mL | 29.0461 mL | 58.0923 mL | 116.1845 mL | 145.2306 mL |
| 5 mM | 1.1618 mL | 5.8092 mL | 11.6185 mL | 23.2369 mL | 29.0461 mL |
| 10 mM | 0.5809 mL | 2.9046 mL | 5.8092 mL | 11.6185 mL | 14.5231 mL |
| 50 mM | 0.1162 mL | 0.5809 mL | 1.1618 mL | 2.3237 mL | 2.9046 mL |
| 100 mM | 0.0581 mL | 0.2905 mL | 0.5809 mL | 1.1618 mL | 1.4523 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rubroside H
Catalog No.:BCN1857
CAS No.:227597-43-5
- Rubroside G
Catalog No.:BCN1856
CAS No.:227597-42-4
- Xanthobaccin A
Catalog No.:BCN1864
CAS No.:227596-81-8
- Mucrolidin
Catalog No.:BCN5072
CAS No.:227471-20-7
- (3S,7S)-5,6-Dehydro-4''-de-O-methylcentrolobine
Catalog No.:BCN1481
CAS No.:227289-51-2
- AZ 11645373
Catalog No.:BCC7646
CAS No.:227088-94-0
- 9-Deacetyl-9-benzoyl-10-debenzoyl-4beta,20-epoxytaxchinin A
Catalog No.:BCN7676
CAS No.:227011-48-5
- Hyponine E
Catalog No.:BCC8999
CAS No.:226975-99-1
- 3,6-Dimethoxyapigenin
Catalog No.:BCN4830
CAS No.:22697-65-0
- Emapunil
Catalog No.:BCC5521
CAS No.:226954-04-7
- LB42708
Catalog No.:BCC5344
CAS No.:226929-39-1
- 4-Hydroxy-1,10-secocadin-5-ene-1,10-dione
Catalog No.:BCN6661
CAS No.:226904-40-1
- (±)-HIP-B
Catalog No.:BCC7295
CAS No.:227619-65-0
- Ethyl 3-(4-methoxyphenyl)propanoate
Catalog No.:BCN4038
CAS No.:22767-72-2
- Z-D-Trp-OH
Catalog No.:BCC2748
CAS No.:2279-15-4
- EPI-001
Catalog No.:BCC6536
CAS No.:227947-06-0
- Ecdysterone 20,22-monoacetonide
Catalog No.:BCN5073
CAS No.:22798-96-5
- Ecdysterone 2,3:20,22-diacetonide
Catalog No.:BCN5074
CAS No.:22798-98-7
- Ac-D-Trp-OH
Catalog No.:BCC3116
CAS No.:2280-01-5
- 1-Hydroxy-2,3,5-trimethoxyxanthone
Catalog No.:BCN6569
CAS No.:22804-49-5
- 1,2,3,7-Tetramethoxyxanthone
Catalog No.:BCN7519
CAS No.:22804-52-0
- 3-(4-Hydroxy-3,5-dimethoxyphenyl)-1,2-propanediol
Catalog No.:BCN1480
CAS No.:22805-15-8
- Alisol K 23-acetate
Catalog No.:BCN3363
CAS No.:228095-18-9
- Boc-Met-OH.DCHA
Catalog No.:BCC2602
CAS No.:22823-50-3
Endoscopic release of internal snapping hip: a review of literature.[Pubmed:28066743]
Muscles Ligaments Tendons J. 2016 Dec 21;6(3):372-377.
BACKGROUND: Internal snapping hip is a common clinical condition, characterized by an audible or palpable snap of the medial compartment of the hip. In most cases it is asymptomatic, while in a few patients, mostly in athletes who participate in activities requiring extremes of hip range of motion, the snap may become painful (internal snapping hip syndrome - ISHS). MATERIALS AND METHODS: This is a review of current literature, focused on the pathogenesis, diagnosis and treatment of ISHS. CONCLUSION: The pathogenesis of ISHS is multifactorial, and it is traditionally believed to be caused by the tendon snapping over the anterior femoral head or the iliopectineal ridge. Most cases of ISHS resolve with conservative treatment, which includes avoidance of aggravating activities, stretching, and NSAIDs. In recalcitrant cases, surgery may be indicated. Better results have been reported with endoscopic iliopsoas tendon release compared with open techniques, which may be related to the treatment of concomitant intra-articular pathologies. Furthermore, endoscopic treatment showed fewer complications, decreased failure rate and postop erative pain. It is important to remember that in most cases, a multiple iliopsoas tendon may exist, and that the incomplete release of the iliopsoas tendon can be a reason for refractory pain and poor results. Then, even if of not clinical relevance at long term follow-up, patients should be told about the inevitable loss of flexion strength after iliopsoas tenotomy. LEVEL OF EVIDENCE: II.
Microinstability of the hip: a previously unrecognized pathology.[Pubmed:28066740]
Muscles Ligaments Tendons J. 2016 Dec 21;6(3):354-360.
BACKGROUND: Hip microinstability is an established diagnosis; however, its occurrence is still debated by many physicians. Diagnosis of hip microinstability is often challenging, due to a lack of specific signs or symptoms, and patients may remain undiagnosed for long periods. This may lead to early manifestation of degenerative joint disease. Consequently, careful patient and family history must be obtained and diagnostic imaging should follow. After a thorough clinical evaluation of the patient with suspected hip microinstability, the physician should focus on how to improve symptoms and functionality in daily and sports activities. PURPOSE: The purpose of this review article was to give a current update regarding this diagnosis and to provide a complete diagnostic approach in order to effectively treat hip microinstability. METHODS: We reviewed the literature on the diagnosis, the non-operative and operative indications for the treatment of this complex and often misdiagnosed pathology. CONCLUSION: Conservative treatment is considered the best initial approach, though, surgical intervention should be considered if symptoms persist or other hip pathology exists. Successful surgical intervention, such as hip arthroscopy, should focus on restoring the normal anatomy of the hip joint in order to regain its functionality. The role of the hip joint capsule has gained particular research interest during the last years, and its repair or reconstruction during hip arthroscopy is considered necessary in order to avoid iatrogenic hip microinstability. Various capsular closure/plication techniques have been developed towards this direction with encouraging results. LEVEL OF EVIDENCE: V.
Imaging of the hip: a systematic approach to the young adult hip.[Pubmed:28066731]
Muscles Ligaments Tendons J. 2016 Dec 21;6(3):265-280.
BACKGROUND: Great advances in knowledge and understanding of the biomechanics of the hip, both in arthroscopic procedures and imaging techniques, have expanded and improved the diagnosis of pathologies of the young adult hip. The anatomy of the hip joint is complex due to its morphology and orientation. The inter-pretation of the images requires deep knowledge of the osseous and soft tissue anatomy: muscles, tendons, ligaments, vessels and nerves. There are multiple imaging tools. Diagnostic techniques have different utilities and often are complementary. METHODS: In this article the various diagnostic imaging techniques for evaluation of hip pathologies are discussed, their indications and usefulness, with emphasis on those resolved arthroscopically. CONCLUSION: Young adult hip disorders are increasingly diagnosed and treated as arthroscopic procedures improved. Radiology is a fundamental contribution in the diagnostic process. Plain radiography (X-ray) is always the initial examination. LEVEL OF EVIDENCE: V.
Cementless Hip Stem Anteversion in the Dysplastic Hip: A Comparison of Tapered Wedge vs Metaphyseal Filling.[Pubmed:28110848]
J Arthroplasty. 2017 May;32(5):1547-1552.
BACKGROUND: Appropriate stem anteversion is important for achieving stability of the prosthetic joint in total hip arthroplasty. Anteversion of a cementless femoral stem is affected by the femoral canal morphology and varies according to stem geometry. We investigated the difference and variation of the increase in anteversion between 2 types of cementless stems, and the correlation between each stem and the preoperative femoral anteversion. METHODS: We retrospectively compared 2 groups of hips that underwent total hip arthroplasty using a metaphyseal filling stem (78 hips) or a tapered wedge stem (83 hips). All the patients had osteoarthritis due to hip dysplasia. Computed tomography was used to measure preoperative femoral anteversion at 5 levels and postoperative stem anteversion. RESULTS: The increase in anteversion of the tapered wedge stem group (22.7 degrees +/- 11.6 degrees ) was more than that of the metaphyseal filling stem group (17.2 degrees +/- 8.3 degrees ; P = .0007). The variation of the increase in the tapered wedge stem group was significantly larger than that in the metaphyseal filling stem group (P = .0016). The metaphyseal filling stem group was more highly and positively correlated with femoral anteversion than the tapered wedge stem group. CONCLUSION: Femoral anteversion affects stem anteversion differently according to stem geometry. The tapered wedge stems had greater variation of the increase in anteversion than did the metaphyseal filling stems. Based on the results of this study, it is difficult to preoperatively estimate the increase in stem anteversion for tapered wedge stems.
